BTBD2

Across TCGA pan-cancer cohorts, BTBD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTBD2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BTBD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BTBD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where BTBD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.856	0.530	<.001	77	view →
LUAD	OS	Median	All	0.609	1.000	<.001	15	view →
CCRCC	OS	Median	All	0.747	0.916	.005	12	view →
PDAC	DFS	Median	III,IV	0.685	0.230	.008	7	view →
GBM	OS	Quartile	All	0.728	0.479	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BTBD2–HNSC (OS)

Open the HNSC breakdown →